The ASCENT-04/KEYNOTE-D19 trial compared the combination of sacituzumab govitecan and pembrolizumab with chemotherapy plus pembrolizumab in patients with untreated, PD-L1-positive, metastatic triple-negative breast cancer.[2] Combination therapy reduced the risk of disease progression or death by 35%, and the median progression-free survival was 11.2 months.[2] The safety profile was manageable and predictable, with a lower rate of dose reduction or discontinuation compared to chemotherapy.[2] Although treatment-related adverse events occurred more frequently in the combination group, their severity was lower.[2] Sacituzumab govitecan is a monoclonal antibody conjugate with chemotherapy that targets DNA damage in cancer cells.[1][7] The study confirms a statistically significant benefit in progression-free survival and overall survival compared to standard chemotherapy.[1]